Pre-order Enquiry
Request Free Sample
United States Oligodendroglioma Treatment Market Report 2018
SKU ID : QYR-11632292 | Publishing Date : 18-Dec-2017 | No. of pages : 114
Request Sample
Request Customization
Check DiscountsDetailed TOC of United States Oligodendroglioma Treatment Market Report 2018
Table of ContentsUnited States Oligodendroglioma Treatment Market Report 2017
1 Oligodendroglioma Treatment Overview
1.1 Product Overview and Scope of Oligodendroglioma Treatment
1.2 Classification of Oligodendroglioma Treatment by Product Category
1.2.1 United States Oligodendroglioma Treatment Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Oligodendroglioma Treatment Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 Alisertib
1.2.4 Bevacizumab
1.2.5 CDX-1401
1.2.6 Dasatinib
1.2.7 DCVax-L
1.2.8 IMA-950
1.2.9 Others
1.3 United States Oligodendroglioma Treatment Market by Application/End Users
1.3.1 United States Oligodendroglioma Treatment Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 ASCs
1.4 United States Oligodendroglioma Treatment Market by Region
1.4.1 United States Oligodendroglioma Treatment Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Oligodendroglioma Treatment Status and Prospect (2012-2022)
1.4.3 Southwest Oligodendroglioma Treatment Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Oligodendroglioma Treatment Status and Prospect (2012-2022)
1.4.5 New England Oligodendroglioma Treatment Status and Prospect (2012-2022)
1.4.6 The South Oligodendroglioma Treatment Status and Prospect (2012-2022)
1.4.7 The Midwest Oligodendroglioma Treatment Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Oligodendroglioma Treatment (2012-2022)
1.5.1 United States Oligodendroglioma Treatment Sales and Growth Rate (2012-2022)
1.5.2 United States Oligodendroglioma Treatment Revenue and Growth Rate (2012-2022)
2 United States Oligodendroglioma Treatment Market Competition by Players/Suppliers
2.1 United States Oligodendroglioma Treatment Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Oligodendroglioma Treatment Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Oligodendroglioma Treatment Average Price by Players/Suppliers (2012-2017)
2.4 United States Oligodendroglioma Treatment Market Competitive Situation and Trends
2.4.1 United States Oligodendroglioma Treatment Market Concentration Rate
2.4.2 United States Oligodendroglioma Treatment Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Oligodendroglioma Treatment Manufacturing Base Distribution, Sales Area, Product Type
3 United States Oligodendroglioma Treatment Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Oligodendroglioma Treatment Sales and Market Share by Region (2012-2017)
3.2 United States Oligodendroglioma Treatment Revenue and Market Share by Region (2012-2017)
3.3 United States Oligodendroglioma Treatment Price by Region (2012-2017)
4 United States Oligodendroglioma Treatment Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Oligodendroglioma Treatment Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Oligodendroglioma Treatment Revenue and Market Share by Type (2012-2017)
4.3 United States Oligodendroglioma Treatment Price by Type (2012-2017)
4.4 United States Oligodendroglioma Treatment Sales Growth Rate by Type (2012-2017)
5 United States Oligodendroglioma Treatment Sales (Volume) by Application (2012-2017)
5.1 United States Oligodendroglioma Treatment Sales and Market Share by Application (2012-2017)
5.2 United States Oligodendroglioma Treatment Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Oligodendroglioma Treatment Players/Suppliers Profiles and Sales Data
6.1 AngioChem Inc
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 AngioChem Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Boehringer Ingelheim GmbH
6.2.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Bristol-Myers Squibb Co
6.3.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Cavion LLC
6.4.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Cavion LLC Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Celldex Therapeutics Inc
6.5.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Celldex Therapeutics Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Eli Lilly and Co
6.6.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Eli Lilly and Co Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 F. Hoffmann-La Roche Ltd
6.7.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Immatics Biotechnologies GmbH
6.8.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Ipsen SA
6.9.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 Ipsen SA Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Leadiant Biosciences Inc
6.10.2 Oligodendroglioma Treatment Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Leadiant Biosciences Inc Oligodendroglioma Treatment Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Millennium Pharmaceuticals Inc
6.12 Northwest Biotherapeutics Inc
6.13 Novartis AG
6.14 Pfizer Inc
6.15 Tocagen Inc
7 Oligodendroglioma Treatment Manufacturing Cost Analysis
7.1 Oligodendroglioma Treatment Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Oligodendroglioma Treatment
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Oligodendroglioma Treatment Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Oligodendroglioma Treatment Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Oligodendroglioma Treatment Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Oligodendroglioma Treatment Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Oligodendroglioma Treatment Sales Volume Forecast by Type (2017-2022)
11.3 United States Oligodendroglioma Treatment Sales Volume Forecast by Application (2017-2022)
11.4 United States Oligodendroglioma Treatment Sales Volume Forecast by Region (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
List of Figures, Tables and Charts Available in United States Oligodendroglioma Treatment Market Report 2018
List of Tables and FiguresFigure Product Picture of Oligodendroglioma Treatment
Figure United States Oligodendroglioma Treatment Market Size (K Pcs) by Type (2012-2022)
Figure United States Oligodendroglioma Treatment Sales Volume Market Share by Type (Product Category) in 2016
Figure Alisertib Product Picture
Figure Bevacizumab Product Picture
Figure CDX-1401 Product Picture
Figure Dasatinib Product Picture
Figure DCVax-L Product Picture
Figure IMA-950 Product Picture
Figure Others Product Picture
Figure United States Oligodendroglioma Treatment Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Oligodendroglioma Treatment by Application in 2016
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure ASCs Examples
Table Key Downstream Customer in ASCs
Figure United States Oligodendroglioma Treatment Market Size (Million USD) by Region (2012-2022)
Figure The West Oligodendroglioma Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Oligodendroglioma Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Oligodendroglioma Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Oligodendroglioma Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Oligodendroglioma Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Oligodendroglioma Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Oligodendroglioma Treatment Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Oligodendroglioma Treatment Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Oligodendroglioma Treatment Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Oligodendroglioma Treatment Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Oligodendroglioma Treatment Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Oligodendroglioma Treatment Sales Share by Players/Suppliers
Figure 2017 United States Oligodendroglioma Treatment Sales Share by Players/Suppliers
Figure United States Oligodendroglioma Treatment Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Oligodendroglioma Treatment Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Oligodendroglioma Treatment Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Oligodendroglioma Treatment Revenue Share by Players/Suppliers
Figure 2017 United States Oligodendroglioma Treatment Revenue Share by Players/Suppliers
Table United States Market Oligodendroglioma Treatment Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Oligodendroglioma Treatment Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Oligodendroglioma Treatment Market Share of Top 3 Players/Suppliers
Figure United States Oligodendroglioma Treatment Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Oligodendroglioma Treatment Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Oligodendroglioma Treatment Product Category
Table United States Oligodendroglioma Treatment Sales (K Pcs) by Region (2012-2017)
Table United States Oligodendroglioma Treatment Sales Share by Region (2012-2017)
Figure United States Oligodendroglioma Treatment Sales Share by Region (2012-2017)
Figure United States Oligodendroglioma Treatment Sales Market Share by Region in 2016
Table United States Oligodendroglioma Treatment Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Oligodendroglioma Treatment Revenue Share by Region (2012-2017)
Figure United States Oligodendroglioma Treatment Revenue Market Share by Region (2012-2017)
Figure United States Oligodendroglioma Treatment Revenue Market Share by Region in 2016
Table United States Oligodendroglioma Treatment Price (USD/Pcs) by Region (2012-2017)
Table United States Oligodendroglioma Treatment Sales (K Pcs) by Type (2012-2017)
Table United States Oligodendroglioma Treatment Sales Share by Type (2012-2017)
Figure United States Oligodendroglioma Treatment Sales Share by Type (2012-2017)
Figure United States Oligodendroglioma Treatment Sales Market Share by Type in 2016
Table United States Oligodendroglioma Treatment Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Oligodendroglioma Treatment Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Oligodendroglioma Treatment by Type (2012-2017)
Figure Revenue Market Share of Oligodendroglioma Treatment by Type in 2016
Table United States Oligodendroglioma Treatment Price (USD/Pcs) by Types (2012-2017)
Figure United States Oligodendroglioma Treatment Sales Growth Rate by Type (2012-2017)
Table United States Oligodendroglioma Treatment Sales (K Pcs) by Application (2012-2017)
Table United States Oligodendroglioma Treatment Sales Market Share by Application (2012-2017)
Figure United States Oligodendroglioma Treatment Sales Market Share by Application (2012-2017)
Figure United States Oligodendroglioma Treatment Sales Market Share by Application in 2016
Table United States Oligodendroglioma Treatment Sales Growth Rate by Application (2012-2017)
Figure United States Oligodendroglioma Treatment Sales Growth Rate by Application (2012-2017)
Table AngioChem Inc Basic Information List
Table AngioChem Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure AngioChem Inc Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure AngioChem Inc Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure AngioChem Inc Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Boehringer Ingelheim GmbH Basic Information List
Table Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure Boehringer Ingelheim GmbH Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Bristol-Myers Squibb Co Basic Information List
Table Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb Co Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Cavion LLC Basic Information List
Table Cavion LLC Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Cavion LLC Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure Cavion LLC Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure Cavion LLC Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Celldex Therapeutics Inc Basic Information List
Table Celldex Therapeutics Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Celldex Therapeutics Inc Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure Celldex Therapeutics Inc Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure Celldex Therapeutics Inc Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Eli Lilly and Co Basic Information List
Table Eli Lilly and Co Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly and Co Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure Eli Lilly and Co Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure Eli Lilly and Co Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table F. Hoffmann-La Roche Ltd Basic Information List
Table F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Immatics Biotechnologies GmbH Basic Information List
Table Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure Immatics Biotechnologies GmbH Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Ipsen SA Basic Information List
Table Ipsen SA Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Ipsen SA Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure Ipsen SA Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure Ipsen SA Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Leadiant Biosciences Inc Basic Information List
Table Leadiant Biosciences Inc Oligodendroglioma Treatment Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Leadiant Biosciences Inc Oligodendroglioma Treatment Sales Growth Rate (2012-2017)
Figure Leadiant Biosciences Inc Oligodendroglioma Treatment Sales Market Share in United States (2012-2017)
Figure Leadiant Biosciences Inc Oligodendroglioma Treatment Revenue Market Share in United States (2012-2017)
Table Millennium Pharmaceuticals Inc Basic Information List
Table Northwest Biotherapeutics Inc Basic Information List
Table Novartis AG Basic Information List
Table Pfizer Inc Basic Information List
Table Tocagen Inc Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Oligodendroglioma Treatment
Figure Manufacturing Process Analysis of Oligodendroglioma Treatment
Figure Oligodendroglioma Treatment Industrial Chain Analysis
Table Raw Materials Sources of Oligodendroglioma Treatment Major Players/Suppliers in 2016
Table Major Buyers of Oligodendroglioma Treatment
Table Distributors/Traders List
Figure United States Oligodendroglioma Treatment Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Oligodendroglioma Treatment Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Oligodendroglioma Treatment Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Oligodendroglioma Treatment Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Oligodendroglioma Treatment Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Oligodendroglioma Treatment Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Oligodendroglioma Treatment Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Oligodendroglioma Treatment Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Oligodendroglioma Treatment Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Oligodendroglioma Treatment Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Oligodendroglioma Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Oligodendroglioma Treatment Sales Volume Share Forecast by Region (2017-2022)
Figure United States Oligodendroglioma Treatment Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
